Bookmark and Share

BioActivity Data for Compound Camphor (CID 2537)

BioActivity Outcomes:
Active(2)
 
 
Inactive(725)
 
 
Inconclusive(33)
 
 
Unspecified(29)
 
 
Top Targets:
7tm 4(36)
 
 
 
NR LBD PPAR(18)
 
 
 
NR LBD AR(11)
 
 
NR LBD TR(11)
 
 
NR LBD ER(11)
 
 
 
BioAssay Types:
Confirmatory(364)
 
 
 
 
 
Screening(309)
 
 
Summary(29)
 
 
 
Literature(13)
 
 
BioAssay Categories:
In vitro(17)
 
 
 
In vivo(3)
 
 
 
Biochemical(121)
 
 
 
Toxicity(59)
 
 
 
 
Cell-based(101)
 
 
 
 
Organism-base..(11)
 
 
 
BioActivity Types:
Potency(340)
 
 
 
 
 
IC50(9)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 695    Data Row: 789   Total Pages: 40   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID26752736]
Potency 1.9953qHTS assay for small molecule agonists of estrogen receptor alpha signaling [AID588514, Type: confirmatory]estrogen nuclear receptor alpha [Homo sapiens] [gi:348019627]
View
2
[SID17389023]
Potency 7.0795qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1) [AID1030, Type: confirmatory]aldehyde dehydrogenase 1 family, member A1 [Homo sapiens] [gi:30582681]
View
3
[SID8149228]
Screen for compounds that correct neuronal dysfunction without cell death as induced by the expression of polyglutamine-expanded, N-terminal huntingtin in C. elegans mechanosensory neurons (HDELENEU) [AID1599, Type: other]
View
4
[SID103179042]
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) [AID625156, Type: other]Neuropeptide Y receptor type 1 [gi:128997]
View
5
[SID103179042]
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) [AID625176, Type: other]Neutrophil elastase [gi:119292]
View
6
[SID49816688]
Potency qHTS for Inhibitors of Human Acid Sphingomyelinase Assay: Native Substrate [AID624178, Type: confirmatory]acid sphingomyelinase [Homo sapiens] [gi:179095]
View
7
[SID103179042]
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) [AID625169, Type: other]
View
8
[SID103179042]
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) [AID625189, Type: other]
View
9
[SID103179042]
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) [AID625211, Type: other]
View
10
[SID103179042]
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) [AID625230, Type: other]
View
11
[SID103179042]
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) [AID625274, Type: other]
View
12
[SID103179042]
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) [AID625265, Type: other]
View
13
[SID8149228]
Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubU) [AID1593, Type: other]
View
14
[SID8149228]
Screen for compounds that selectively inhibit cytochrome c release from purified mitochondria (CytoCRel) [AID1603, Type: other]
View
15
[SID8149228]
Screen for compounds that inhibit polyglutamine induced protein aggregation (AGREG) [AID1604, Type: other]
View
16
[SID8149228]
Screening of compounds showing protective effect against cell death induced by familial amyotrophic lateral sclerosis (FALS)-linked mutantsuperoxide dismutase 1 (SOD1) (ALSOD1) [AID1605, Type: other]
View
17
[SID8149228]
Screen for compounds that increase glutamate transport activity in MN-1 cell line (GluUPTAKE) [AID1612, Type: other]
View
18
[SID8149228]
Screen for compounds that inhibit protein aggregation formed by mutant SOD1 (GFPSOD1) [AID1613, Type: other]
View
19
[SID8149228]
Screen for compounds that reduce polyglutamine (polyQ) inclusions in nerve growth factor (NGF)-treated PC12 cells (GFPQ80) [AID1614, Type: other]
View
20
[SID8149228]
Yeast cell-based screen for compounds that suppress polyglutamine aggregation in vivo (75Q-TubH) [AID1616, Type: other]
View